Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial
Gregg W Stone,JoAnn Lindenfeld,Josep Rodés-Cabau,Stefan D Anker,Michael R Zile,Saibal Kar,Richard Holcomb,Michael P Pfeiffer,Antoni Bayes-Genis,Jeroen J Bax,Alan J Bank,Maria Rosa Costanzo,Stefan Verheye,Ariel Roguin,Gerasimos Filippatos,Julio Núñez,Elizabeth C Lee,Michal Laufer-Perl,Gil Moravsky,Sheldon E Litwin,Edgard Prihadi,Hemal Gada,Eugene S Chung,Matthew J Price,Vinay Thohan,Dimitry Schewel,Sachin Kumar,Stephan Kische,Kevin S Shah,Daniel J Donovan,Yiran Zhang,Neal L Eigler,William T Abraham,RELIEVE-HF Investigators,John Gorcsan,Marrick Kukin,Kunjan Bhatt,David Shavelle,Liviu Klein,Alicia Romero,Garrie Haas,Vijay Swarup,Elizabeth Volz,Fareed Collado,Amit Badiye,Luanda Grazette,Michelle Hamilton,Tom McRae,Sumant Lamba,Steven Krueger,Timothy Byrne,Leslie Miller,Youssef Al-Saghir,Robin Chand,Saeb Khoury,Ira Dauber,Sula Mazimba,Suneet Mittal,Steven Driver,Stanislav Weiner,Samir Kapadia,Priyanka Gosain,Rajeev Singh,Zvonimir Krejcer,Lynn Punnoose,Stuart Russell,Maria Karas,Gautam Kumar,Ajith Nair,Robert Widmer,Ramesh Kundur,Nabil Dib,Ugochukwu Egolum,Miguel Alvarez Villela,John Boehmer,George Petrossian,Jeffrey Teuteberg,Peter Bittenbender,Ignacio Amat Santos,Ana Garcia,Maria Del Trigo,Sònia Pérez Mirabet,Luis Nombela,Domingo Pascual Figal,Israel Gotsman,Wadi Kinany,Sorel Goland,Dov Freimark,Tal Hasin,Oren Caspi,Eli Lev,Hilmi Alnsasra,Burkhard Sievers,Mohammad Sherif,Karl Fengler,Rolf Wachter,Ince Hüseyin,Jörg Hausleiter,Ralf Stephan Von Bardeleben,Reda Ibrahim,Eric Horlick,Bartosz Krakowiak,Adam Witkowski,Wojciech Wojakowski,Jan Van Der Heyden,Nicholas Van Mieghem,Martijn Post,Carmine DePasquale,Frank Ruschitzka,Richard Troughton
DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.070870
IF: 37.8
2024-09-23
Circulation
Abstract:Background: An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms and prognosis. Methods: Patients with symptomatic HF with any left ventricular ejection fraction (LVEF) were randomized 1:1 to transcatheter shunt implantation versus a placebo procedure, stratified by reduced (≤40%) versus preserved (>40%) LVEF. The primary safety outcome was a composite of device-related or procedure-related major adverse cardiovascular or neurological events at 30 days compared with a prespecified performance goal of 11%. The primary effectiveness outcome was the hierarchical composite ranking of all-cause death, cardiac transplantation or left ventricular assist device implantation, HF hospitalization, outpatient worsening HF events, and change in quality of life from baseline measured by the Kansas City Cardiomyopathy Questionnaire overall summary score through maximum 2-year follow-up, assessed when the last enrolled patient reached 1-year follow-up, expressed as the win ratio. Prespecified hypothesis-generating analyses were performed on patients with reduced and preserved LVEF. Results: Between October 24, 2018, and October 19, 2022, 508 patients were randomized at 94 sites in 11 countries to interatrial shunt treatment (n=250) or a placebo procedure (n=258). Median (25th and 75th percentiles) age was 73.0 years (66.0, 79.0), and 189 patients (37.2%) were women. Median LVEF was reduced (≤40%) in 206 patients (40.6%) and preserved (>40%) in 302 patients (59.4%). No primary safety events occurred after shunt implantation (upper 97.5% confidence limit, 1.5%; P<0.0001). There was no difference in the 2-year primary effectiveness outcome between the shunt and placebo procedure groups (win ratio, 0.86 [95% CI, 0.61-1.22]; P=0.20). However, patients with reduced LVEF had fewer adverse cardiovascular events with shunt treatment versus placebo (annualized rate 49.0% versus 88.6%; relative risk, 0.55 [95% CI, 0.42-0.73]; P<0.0001), whereas patients with preserved LVEF had more cardiovascular events with shunt treatment (annualized rate 60.2% versus 35.9%; relative risk, 1.68 [95% CI, 1.29-2.19]; P=0.0001; Pinteraction<0.0001). There were no between-group differences in change in Kansas City Cardiomyopathy Questionnaire overall summary score during follow-up in all patients or in those with reduced or preserved LVEF. Conclusions: Transcatheter interatrial shunt implantation was safe but did not improve outcomes in patients with HF. However, the results from a prespecified exploratory analysis in stratified randomized groups suggest that shunt implantation is beneficial in patients with reduced LVEF and harmful in patients with preserved LVEF. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03499236.